Pluri

Pluri Biotech is a publicly traded company that specializes in the development and manufacturing of next-generation cell-based products. Their patented technology focuses on 3D cell expansion platforms, which allow for the efficient and cost-effective growth of cells. This innovative approach can be applied to a variety of cell types, including plant, animal, and human cells, making it versatile and applicable across a range of industries.

The company operates in the biotechnology market, serving clients from various sectors that require cell-based products. This could include medical and pharmaceutical companies, research institutions, and potentially even agricultural or environmental organizations. Their business model revolves around leveraging their unique technology to provide superior cell growth solutions, which they then sell to their clients.

Pluri Biotech's revenue is generated through the sale of their cell-based products and the licensing of their patented 3D cell expansion technology. As a public company, they also raise funds through the issuance of securities, which are traded on the Tel Aviv Stock Exchange and Nasdaq.

In summary, Pluri Biotech is a pioneering company in the biotech industry, harnessing the power of nature to create efficient and cost-effective cell growth solutions. Their innovative approach and versatile technology position them well to serve a broad range of clients and industries.

Keywords: Biotechnology, 3D Cell Expansion, Patented Technology, Cell-Based Products, Public Company, Securities, Tel Aviv Stock Exchange, Nasdaq, Efficient Cell Growth, Versatile Applications.